logo
Plus   Neg
Share
Email
Comment

Novartis To Add Warning On Blood Pressure Drug Rasilez On CHMP Recommendation

Novartis AG (NVS) Friday reported the conclusion of a risk-benefit review of its high blood pressure drug Rasilez by the European Medicines Agency's, or EMA's, Committee for Medicinal Products for Human Use, or CHMP. The Committee recommended that the product information for Rasilez in the EU should warn against use by patients who are also taking an ACE inhibitor or an ARB.

The review, which followed Novartis's decision to terminate its ALTITUDE study in the wake of a high incidence of adverse events, found that patients who have diabetes or mild-to-moderate renal impairment should consult a physician before using a combination product containing aliskiren, for which Rasilez is the trade name. The update also applies to other aliskiren products such as Sprimeo, Riprazo and Rasilamlo.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Google plans to commission three underwater cables in 2019 as part of efforts to expand its cloud business amid stiff competition from rivals Microsoft and Amazon. The three fiber-optic subsea cables will run across different routes. Google noted that it has spent $30 billion to improve its infrastructure over three years. McDonald's Corp. said Tuesday that all of its packaging worldwide will come from renewable, recycled or certified sources by 2025, up from the current figure of 50 percent. The fast food giant also aims to recycle guest packaging in all its restaurants by then, compared with only 10 percent of its restaurants currently. General Electric Co. (GE) will take an after-tax charge of $6.2 billion in its fourth quarter results as part of comprehensive review of its finance arm's insurance portfolio. The after-tax charge will be $7.5 billion when adjusted to the rate following the recent U.S. tax overhaul.
comments powered by Disqus
Follow RTT